Liberty Biopharma Closes Private Placement
Richmond, British Columbia (FSCwire) - Liberty Biopharma Inc. (“Liberty Biopharma” or
the “Company”) (TSXV: LTY) announces that it has closed a non-brokered private placement consisting of the issuance of 2,580,000
common shares to one (1) investor at a price of $0.15 per common share for gross proceeds of $387,000 (“Private
Placement”).
A commission of 258,000 common shares of the Company will be issued to Red Rock Global Capital Ltd. of New York, New York, the
arm’s length finder for arranging the Private Placement. The commission is subject to acceptance by the TSX Venture
Exchange (the “Exchange”).
The Private Placement is subject to acceptance by the Exchange. All securities issued under the Private Placement will
be subject to a hold period expiring four months and one day from the date of issuance.
About Liberty Biopharma Inc.
Liberty Biopharma is a medical digital technology and biopharmaceutical company active in global strategic partnerships and
in-licensing of technologies and assets for rapid growth and high value solutions.
Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the Policies of
the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
For further information, please contact:
Liberty Biopharma Inc.
Alan Tam, CPA, CA
Chief Financial Officer
Telephone: (604) 604-377-7575
To view the original release, please click here
Source: Liberty Biopharma Inc. (TSX Venture:LTY)
To follow Liberty Biopharma Inc. on your favorite social media platform or financial websites, please click on the icons
below.
Maximum News Dissemination by FSCwire. https://www.fscwire.com
Copyright © 2018 FSCwire
